Zydus Cadila receives tentative approval from USFDA for Tofacitinib Extended-Release Tablets

Zydus Cadila has received tentative approval from the USFDA to market Tofacitinib Extended-Release Tablets, 11 mg (US RLD: Xeljanz XR® Tablets). It is recommended for the once-daily treatment of adult patients with moderately to severely active ulcerative colitis (UC).

The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad.

The group now has 308 approvals and has so far filed over 390 ANDAs since the commencement of the filing process in FY 2003-04.

Shares of CADILA HEALTHCARE LTD. was last trading in BSE at Rs.430.55 as compared to the previous close of Rs. 415.6. The total number of shares traded during the day was 166413 in over 3239 trades.

The stock hit an intraday high of Rs. 432.2 and intraday low of 412. The net turnover during the day was Rs. 70759142.

Source : Equity Bulls

Keywords